Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older~2. Patient or guardian able to provide a signed witnessed informed consent~3. Stenosis greater than or equal to 50% treated satisfactorily (less than 20% residual stenosis) with balloon angioplasty alone or balloon angioplasty and stent placement~4. Either gender~Exclusion Criteria:~1. Women who are pregnant or who are expected to or might become pregnant~2. Women of child-bearing potential who do not use contraception~3. Life expectancy less than 12 months~4. Known allergy to paclitaxel~5. Known allergy to contrast media not previously demonstrated to be controllable with premedication on a prior study using contrast~6. Known allergy to the pre-medications (dexamethasone, famotidine, diphenhydramine)~7. Pre-fistulogram thrombosis of the fistula or graft~8. Thrombectomy of the fistula or graft within 14 days of the procedure~9. Patient receiving chemotherapy~10. Patients with an immunodeficiency disease or condition~11. Documented hypercoagulable state~12. White Blood Count \< 2000/mm3~13. Platelet count less than 100,000/mm3~14. Chronic hepatitis or jaundice (total bilirubin \> 2x upper limit of normal)~15. Simultaneous enrollment in another investigational device or drug study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Therapy Alone (Type: SHAM_COMPARATOR): Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this control group, no paclitaxel is administered. The sham treatment is a period of 10 minutes that is allowed to elapse followed by the performance of a final completion angiogram to be labeled as PaciFIST Study Completion Angiogram. Any additional lesions identified with this study are then treated appropriately following standard technique.
- Standard Therapy Plus Paclitaxel (Type: ACTIVE_COMPARATOR): Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (\>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).~For this treatment group, Paclitaxel solution treatment of each lesion encountered from proximal to distal will be attempted until the 20 mg Paclitaxel dose limit is met.

Based on this trial design, predict the completion outcome and termination type (if applicable).